X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EO2463, an innovative off-the-shelf immunotherapy candidate, is being assessed in early-stage clinical trials with patients for the treatment of follicular lymphoma and marginal zone lymphoma in combination with lenalidomide/rituximab.
Lead Product(s): EO2463,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: EO2463
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
EO2401 is a novel microbiome-derived therapeutic vaccine. It is being evaluated in combination with nivolumab & an anti-VEGF therapy bevacizumab for the treatment of patients with recurrent glioblastoma.
Lead Product(s): EO2401,Nivolumab,Bevacizumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
EO2040, an innovative, off-the-shelf immunotherapy that combines two synthetic OncoMimics™ peptides, is being developed in combination with nivolumab and as a monotherapy in patients with ctDNA defined minimal residual disease stage II-IV colorectal cancer.
Lead Product(s): EO2040,Nivolumab
Therapeutic Area: Oncology Product Name: EO2040
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
EO4010 is an innovative, off-the-shelf immunotherapy that combines five synthetic OncoMimics™ peptides. which is investigated for the treatment of Metastatic Colorectal Cancer.
Lead Product(s): EO4010,Nivolumab
Therapeutic Area: Oncology Product Name: EO4010
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer.
Lead Product(s): EO2401,Nivolumab,Bevacizumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Labcorp Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
EO2401 is a first-in-class OncoMimics™ peptide-based immunotherapy able to rapidly activate and significantly expand existing effector memory CD8+ T cells against tumor-associated driver antigens due to their strong cross-reactivity with OncoMimics™ peptides.
Lead Product(s): EO2401,Nivolumab,Bevacizumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
EO2401 is first-in-class off-shelf peptide-based immunotherapy, combines three microbial-derived closely mimic specific cytotoxic T cell epitopes on Tumor-Associated Antigens IL13Ra2, BIRC5 and FOXM1, combined with the helper peptide Universal Cancer Peptide 2 (UCP2).
Lead Product(s): EO2401,Nivolumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics™ peptide-based immunotherapy. EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with efficacy.
Lead Product(s): EO2401,Nivolumab,Bevacizumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics™ cancer immunotherapy. It combines three OncoMimics™ peptides that closely mimic IL13Ra2, BIRC5 and FOXM1, which are known driver antigens present on aggressive solid tumors.
Lead Product(s): EO2401,Nivolumab,Bevacizumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
EO2401 in combination with nivolumab has demonstrated strong immune responses and clinical efficacy in patients with ACC, which was defined retrospectively using a set of clinical parameters.
Lead Product(s): EO2401,Nivolumab
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
